ABL1 E279K

CI-VAR-00000709Explore in graph →NP_005148.2:p.Glu279LysNM_005157.5:c.835G>ACIViC 1526

Curated evidence

Evidence by cancer (4 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–4 of 4 evidence items across 1 cancer context on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Chronic Myeloid Leukemia, BCR-ABL1 Positive4
BCR::ABL1 Fusion AND ABL1 E279K	Axitinib	Predictive	D	Supports Sensitivity Response	2	accepted	EID7772 In a proliferation assay measuring tritiated thymidine incorporation in the presence of axitinib, Ba/F3 cells carrying the BCR-ABL1 variant showed similar incorporation when harboring fusions with the… (full text at CIViC) PMID 25686603 · Pemovska et al., 2015 · Open in CIViC	civic
BCR::ABL1 Fusion AND ABL1 E279K	Bosutinib	Predictive	D	Supports Sensitivity Response	2	submitted	EID4542 In an in vitro study, a Ba/F3 murine cell line stably expressing the E279K mutation in the ABL1 portion of the BCR-ABL1 fusion protein was associated with sensitivity to bosutinib treatment (IC50: 39.… (full text at CIViC) PMID 19075254 · Redaelli et al., 2009 · Open in CIViC

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.